Seizures in people with Alzheimer's disease are increasingly recognized to worsen disease burden and accelerate functional decline. Harnessing established antiseizure medicine discovery strategies in rodents with Alzheimer's disease associated risk genes represents a novel way to uncover disease modifying treatments that may benefit these Alzheimer's disease patients. This commentary discusses the recent evaluation by Dejakaisaya and colleagues to assess the antiseizure and disease-modifying potential of the repurposed cephalosporin antibiotic, ceftriaxone, in the Tg2576 mouse model. The use of established epilepsy models in Alzheimer's disease research carries the potential to advance novel disease-modifying treatments.
van DyckCHSwansonCJAisenP, et al.Lecanemab in early Alzheimer's disease. N Engl J Med2023; 388: 9–21.
3.
VosselKATartagliaMCNygaardHB, et al.Epileptic activity in Alzheimer's disease: causes and clinical relevance. Lancet Neurol2017; 16: 311–322.
4.
AmatniekJCHauserWADelCastillo-CastanedaC, et al.Incidence and predictors of seizures in patients with Alzheimer's disease. Epilepsia2006; 47: 867–872.
5.
ScarmeasNHonigLSChoiH, et al.Seizures in Alzheimer disease: who, when, and how common?Arch Neurol2009; 66: 992–997.
6.
LamADDeckGGoldmanA, et al.Silent hippocampal seizures and spikes identified by foramen ovale electrodes in Alzheimer's disease. Nat Med2017; 23: 678–680.
7.
ZareaACharbonnierCRovelet-LecruxA, et al.Seizures in dominantly inherited Alzheimer disease. Neurology2016; 87: 912–919.
8.
LisgarasCPScharfmanHE. High-frequency oscillations (250–500 Hz) in animal models of Alzheimer's disease and two animal models of epilepsy. Epilepsia2023; 64: 231–246.
9.
SanchezPEZhuLVerretL, et al.Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proc Natl Acad Sci U S A2012; 109: E2895–E2903.
10.
PalopJJChinJRobersonED, et al.Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron2007; 55: 697–711.
11.
HuTXiaoZMaoR, et al.Navbeta2 knockdown improves cognition in APP/PS1 mice by partially inhibiting seizures and APP amyloid processing. Oncotarget2017; 8: 99284–99295.
12.
StephensGSParkJEagleA, et al.Persistent ΔFosB expression limits recurrent seizure activity and provides neuroprotection in the dentate gyrus of APP mice. Prog Neurobiol2024; 237: 102612.
13.
BeckmanMKnoxKKonevalZ, et al.Loss of presenilin 2 age-dependently alters susceptibility to acute seizures and kindling acquisition. Neurobiol Dis2020; 136: 104719.
14.
Vande VyverMBarker-HaliskiMAourzN, et al.Higher susceptibility to 6 Hz corneal kindling and lower responsiveness to antiseizure drugs in mouse models of Alzheimer's disease. Epilepsia2022; 63: 2703–2715.
15.
LehmannLMBarker-HaliskiM. Loss of normal Alzheimer's disease-associated Presenilin 2 function alters antiseizure medicine potency and tolerability in the 6-hz focal seizure model. Front Neurol2023; 14: 1223472.
16.
GoddardGVMcIntyreDCLeechCK. A permanent change in brain function resulting from daily electrical stimulation. Exp Neurol1969; 25: 295–330.
17.
GoddardGV. Development of epileptic seizures through brain stimulation at low intensity. Nature1967; 214: 1020–1021.
18.
SutulaTP. Experimental models of temporal lobe epilepsy: new insights from the study of kindling and synaptic reorganization. Epilepsia1990; 31: S45–S54.
19.
SutulaTHeXXCavazosJ, et al.Synaptic reorganization in the hippocampus induced by abnormal functional activity. Science1988; 239: 1147–1150.
20.
SangdeePTurkanisSAKarlerR. Kindling-like effect induced by repeated corneal electroshock in mice. Epilepsia1982; 23: 471–479.
21.
PinelJPMuchaRFPhilipsAG. Spontaneous seizures generated in rats by kindling: a preliminary report. Physiol Psychol1975; 3: 127–129.
22.
LoscherW. Animal models of seizures and epilepsy: past, present, and future role for the discovery of antiseizure drugs. Neurochem Res2017; 42: 1873–1888.
23.
LoscherW. Fit for purpose application of currently existing animal models in the discovery of novel epilepsy therapies. Epilepsy Res2016; 126: 157–184.
24.
PotschkaHLoscherW. Corneal kindling in mice: behavioral and pharmacological differences to conventional kindling. Epilepsy Res1999; 37: 109–120.
25.
BrandtCEbertULoscherW. Epilepsy induced by extended amygdala-kindling in rats: lack of clear association between development of spontaneous seizures and neuronal damage. Epilepsy Res2004; 62: 135–156.
26.
SayinUOstingSHagenJ, et al.Spontaneous seizures and loss of axo-axonic and axo-somatic inhibition induced by repeated brief seizures in kindled rats. J Neurosci2003; 23: 2759–2768.
27.
LoewenJLBarker-HaliskiMLDahleEJ, et al.Neuronal injury, gliosis, and glial proliferation in two models of temporal lobe epilepsy. J Neuropathol Exp Neurol2016; 75: 366–378.
28.
AlbertiniGWalraveLDemuyserT, et al.6 Hz corneal kindling in mice triggers neurobehavioral comorbidities accompanied by relevant changes in c-fos immunoreactivity throughout the brain. Epilepsia2018; 59: 67–78.
29.
MollerCWolfFvan DijkRM, et al.Toward evidence-based severity assessment in rat models with repeated seizures: I. Electrical kindling. Epilepsia2018; 59: 765–777.
30.
SutulaTP. Secondary epileptogenesis, kindling, and intractable epilepsy: a reappraisal from the perspective of neural plasticity. Int Rev Neurobiol2001; 45: 355–386.
31.
KlitgaardHMatagneAGobertJ, et al.Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur J Pharmacol1998; 353: 191–206.
32.
BakkerAKraussGLAlbertMS, et al.Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment. Neuron2012; 74: 467–474.
33.
VosselKRanasingheKGBeagleAJ, et al.Effect of levetiracetam on cognition in patients with Alzheimer disease with and without epileptiform activity: a randomized clinical trial. JAMA Neurol2021; 78: 1345–1354.
34.
SenAAkinolaMTaiXY, et al.An Investigation of Levetiracetam in Alzheimer's Disease (ILiAD): a double-blind, placebo-controlled, randomised crossover proof of concept study. Trials2021; 22: 508.
35.
LehmannLLoAKnoxKM, et al.Alzheimer's disease and epilepsy: a perspective on the opportunities for overlapping therapeutic innovation. Neurochem Res2021; 46: 1895–1912.
36.
KamenetzFTomitaTHsiehH, et al.APP Processing and synaptic function. Neuron2003; 37: 925–937.
37.
CirritoJRYamadaKAFinnMB, et al.Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron2005; 48: 913–922.
38.
PozoDKnoxALehmannKM, , et al.Chronic evoked seizures in young pre-symptomatic APP/PS1 mice induce serotonin changes and accelerate onset of Alzheimer's disease-related neuropathology. Prog Neurobiol2024; 235: 102591.
39.
ZottBSimonMMHongW, et al.A vicious cycle of beta amyloid-dependent neuronal hyperactivation. Science2019; 365: 559–565.
40.
Barker-HaliskiMWhiteHS. Glutamatergic mechanisms associated with seizures and epilepsy. Cold Spring Harb Perspect Med2015; 5: a022863.
41.
KleinPDingledineRAronicaE, et al.Commonalities in epileptogenic processes from different acute brain insults: Do they translate?Epilepsia2018; 59: 37–66.
42.
WilcoxKSVezzaniA. Does brain inflammation mediate pathological outcomes in epilepsy?Adv Exp Med Biol2014; 813: 169–183.
43.
DevinskyOVezzaniANajjarS, et al.Glia and epilepsy: excitability and inflammation. Trends Neurosci2013; 36: 174–184.
44.
PraterKEGreenKJMamdeS, et al.Human microglia show unique transcriptional changes in Alzheimer's disease. Nat Aging2023; 3: 894–907.
45.
SillsGJRogawskiMA. Mechanisms of action of currently used antiseizure drugs. Neuropharmacology2020; 168: 107966.
46.
LynchBALambengNNockaK, et al.The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A2004; 101: 9861–9866.
47.
DejakaisayaHLinRHarutyunyanA, et al.Effect of ceftriaxone on the glutamate-glutamine cycle and seizure susceptibility of Tg2576 mouse model of Alzheimer's disease. J Alzheimers Dis2024; 102: 370–381.
48.
FanSXianXLiL, et al.Ceftriaxone improves cognitive function and upregulates GLT-1-related glutamate-glutamine cycle in APP/PS1 mice. J Alzheimers Dis2018; 66: 1731–1743.
49.
GaoJLiuLLiuC, et al.GLT-1 knockdown inhibits ceftriaxone-mediated improvements on cognitive deficits, and GLT-1 and xCT expression and activity in APP/PS1 AD mice. Front Aging Neurosci2020; 12: 580772.
